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Restless Legs Syndrome Shows Increased
Silent Postmortem Cerebral Microvascular
Disease With Gliosis
Arthur S. Walters , MD; Paisit Paueksakon, MD; Charles H. Adler , MD, PhD; Michael Moussouttas, MD;
Leonard B. Weinstock , MD; Karen Spruyt , PhD; Kanika Bagai, MD, MSCI
BACKGROUND: Patients with restless legs syndrome (RLS) have increased silent microvascular disease by magnetic resonance
imaging. However, there has been no previous autopsy confirmation of these magnetic resonance imaging findings. RLS is
also frequently associated with inflammatory and immunologically mediated medical disorders. The postmortem cortex in
patients with RLS was therefore evaluated for evidence of microvascular and immunological changes.
METHODS AND RESULTS: Ten microvascular injury samples of precentral gyrus in 5 patients with RLS (3 men, 2 women; mean
age, 81 years) and 9 controls (2 men, 7 women; mean age, 90 years) were studied by hematoxylin and eosin stains in a blinded
fashion. None of the subjects had a history of stroke or neurologic insults. In a similar manner, the following immunohistochemistry stains were performed: (1) glial fibrillary acidic protein (representing gliosis, reactive change of glial cells in response
to damage); (2) CD3 (a T-cell marker); (3) CD19 (a B-cell marker); (4) CD68 (a macrophage marker); and (5) CD117 (a mast cell
marker). Patients with RLS had significantly greater silent microvascular disease (P=0.015) and gliosis (P=0.003). T cells were
increased in RLS compared with controls (P=0.009) and tended to colocalize with microvascular disease (P=0.003). Other
markers did not differ. There was no correlation between microvascular lesion load and RLS severity or duration.
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CONCLUSIONS: Patients with RLS had statistically significantly more silent cerebral microvascular disease and gliosis than
controls compatible with previous magnetic resonance imaging studies and with studies showing a link between RLS and
hypertension, clinical stroke, and cardiovascular disease. T-cell invasion may be a secondary phenomenon.
Key Words: cortex ■ gliosis ■ microvascular disease ■ restless legs syndrome ■ T cells

N

umerous studies over the past decade and
more have suggested that restless legs syndrome (RLS) is associated with hypertension,
heart disease, and stroke.1,2 Magnetic resonance
images, for example, have shown that RLS and its
accompanying periodic limb movements in sleep
are characterized by greater levels of silent cerebral microvascular disease, a known risk factor for
stroke.3,4 However, there has been no previous autopsy confirmation of these magnetic resonance
imaging findings, which is one of the goals of the
current study.

Another trajectory of research has been an investigation into the relationship of RLS with inflammatory
and immunologic disorders. Many of the comorbid
disorders more frequently associated with RLS have
an inflammatory or autoimmune diathesis, including
multiple sclerosis, rheumatoid arthritis, celiac disease,
Crohn disease, inflammatory bowel disease, small intestinal bacterial overgrowth, and, most recently, mast
cell activation syndrome.5–9 Mast cells play a role in allergy, anaphylaxis, wound healing, angiogenesis, immune tolerance, and defense against pathogens.9 The
primary goal of the current study is to document with
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CLINICAL PERSPECTIVE
What Is New?

• Previous work has shown that patients with
restless legs syndrome (RLS) and its frequently
co-occurring periodic limb movements in sleep
have more silent cerebral microvascular disease by magnetic resonance imaging; RLS has
also been associated with inflammation and
autoimmunity.
• To our knowledge there has been no autopsy
confirmation of the magnetic resonance imaging findings and no autopsy study looking for
autoimmune markers in RLS; in this autopsy
study of the cerebral cortex, we show that there
is more silent microvascular disease and accompanying gliosis in patients with RLS versus
controls.
• T-cell invasion reflective of cellular autoimmunity
is also more prominent, and there is no upregulation of CD19 (a B-cell marker), CD68 (a macrophage marker), or CD117 (a mast cell marker).

What Are the Clinical Implications?
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• This study is compatible with previous magnetic
resonance imaging studies and with studies
showing a link between RLS and hypertension,
clinical stroke, and cardiovascular disease.
• This study is also compatible with our previous
study showing that the treatment of RLS with
RLS medications lowers the associated cardiovascular risk.
• Upregulated T-cell levels in patients with RLS
could be predisposing factors for development of microvascular disease or a secondary
phenomenon.

Nonstandard Abbreviations and Acronyms
AZSAND Arizona Study of Aging and
Neurodegenerative Disorders
RLS
restless legs syndrome

postmortem examination the degree of silent cerebral
microvascular disease and gliosis in RLS. The precentral gyrus (motor cortex) was chosen, as neurophysiologic studies have used it as a focus of interest in
showing that suprasegmental disinhibition is a major
feature of RLS.10 A secondary goal, based on previous
studies demonstrating links between RLS and inflammatory and autoimmunity mechanisms, was to determine if inflammatory markers are also present in RLS
cortex, and third, to see if microvascular lesions and
inflammatory markers colocalize.

RLS and Cerebral Microvascular Disease

METHODS
Data, Materials, and Code Disclosure
Statement
The data that support the findings of this study are
available from Paisit Paueksakon, MD, Professor,
Associate Director Division of Renal Pathology/
Electron Microscopy and Renal Pathology Fellowship,
Division of Neuropathology, Department of Pathology,
Microbiology, and Immunology, Vanderbilt University
Medical Center (C-23188 Medical Center North, 1161
21st Ave South, Nashville, TN 37232, Tel: 615-
322-
1350; FAX, 615-322-4840; E-mail: Paisit.Paueksakon@
VUMC.org).
A review of the protocol for this study was done by
the Vanderbilt University Medical Center Institutional
Review Board and was declared “nonresearch” from
an Institutional Review Board point of view, and no informed consent was required.
Precentral gyrus (motor cortex) samples were
obtained from 5 patients with RLS and 9 controls from the AZSAND (Arizona Study of Aging and
Neurodegenerative Disorders) and the Banner Sun
Health Research Institute Brain and Body Donation
Program.11 Subjects were defined as having RLS if they
met the 4 basic clinical criteria for RLS: (1) an urge to
move the legs, (2) worsening of symptoms later in the
day or at night, (3) worsening of symptoms when lying
or sitting, and (4) at least partial and temporary relief
by activity. Those who did not meet the criteria for RLS
qualified as controls.
All subjects completed a movement disorders examination with questions regarding RLS as well as
the Mayo Sleep Questionnaire.11 The subjects chosen all had a long-standing history of RLS. The severity of RLS was rated within ≈3 years of death by the
International Restless Legs Severity Scale. Subjects
had to meet the criteria above for RLS to be administered the International Restless Legs Severity Scale.
The International Restless Legs Severity Scale is a
previously validated instrument consisting of 10 questions, where each question is rated from 0 (no RLS
symptoms) to 4 (maximum RLS severity), and then the
scores for each individual question are added to obtain
a total score (0=no RLS symptoms to 40=maximum
RLS symptoms).12

Exclusion Criteria
In a first round of exclusions, subjects and controls
with a known clinical history of previous stroke or a
history of Alzheimer disease, dementia, head trauma,
Parkinson disease, brain tumor, multiple sclerosis,
or other neurodegenerative disorders were excluded
from the study. In a second round of exclusions, subjects and controls who had neuropathologic evidence
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of stroke, Alzheimer disease, other dementia, head
trauma, Parkinson disease, brain tumor, multiple
sclerosis, or other neurodegenerative disease were
excluded, and at this stage, 1 subject was excluded
because of intraparenchymal hemorrhage.

RLS and Cerebral Microvascular Disease

RLS severity to microvascular lesion load was performed by Spearman’s rho. Post hoc, we calculated
the Hedges’ g, which is an effect-size measure, and
calculated the power of that effect size.
Statistical analyses were performed with Statistica
version 13 (TIBCO Software Inc, Palo Alto, CA).

Studies performed on specimens:
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1. Microvascular injuries (such as intimal fibrosis of
arteries, which correlates with vascular smooth
muscle hyperplasia) with hematoxylin and eosin
stain.
2. Glial fibrillary acidic protein to look for gliosis, which
is a response to brain injury and is a proliferation or
hypertrophy of the glial cells, which are supporting
cells to the neurons.
3. CD3—look for increase in T cells (cellular immunity).
4. CD19—look for increase in B cells (humoral immunity or antibodies).
5. CD68—look for increase in macrophages (first-line
immunologic attack cells).
6. CD 117—look for increase in mast cells (play multiple
roles in immunologic mechanisms).
7. Amyloid beta-
peptide and tau protein to look for
neuritic plaques and neurofibrillary tangles to exclude past brain injury from Alzheimer disease.
8. Ten areas of precentral gyrus of cortex (the motor
cortex) were examined in a blinded fashion for each
subject and rated 0 to 3+ for each entity of interest
by previously described methods.13 The total of ratings for each of 10 areas per patient were added
to get the sum score and then divided by 10 to get
the average. In the above system, 0= no markers
of interest; 1=1 marker of interest; 2=2 to 5 markers
of interest; and 3=>5 markers of interest. If an immunologic marker showed a statistically significant
difference between subjects with RLS and controls,
colocalization of immunologic markers and microvascular disease was determined by the number of
immunologic markers per vascular cross section by
the same methodology.
A detailed description of tissue processing and immunohistochemistry including light microscopy and immunohistochemical studies can be found in Data S1.

Statistical Analysis
A stepwise analytic approach was conducted. Primary
variables were microvascular lesion load and gliosis. Secondary variables were inflammatory markers.
Tertiary variables were RLS duration and severity and
past medical history. The Mann-Whitney U test was
applied to assess group differences for continuous
variables, and Fisher’s exact text was applied for categorical variables. The correlation of RLS duration and

RESULTS
We evaluated 5 RLS patients (3 men and 2 women;
mean age, 81 years; range, 65–93 years) and 9 controls (2 men and 7 women; mean age, 90.2 years;
range, 78–99 years). Table 1 gives the demographic information for subjects and controls in the study. There
was no statistically significant difference in age or sex
between patients and controls (Table 1). Of the 5 subjects who had RLS, 1 subject was on hydrocodone,
1 on clonazepam, 1 on both ropinirole and tramadol
for treatment of RLS, and 2 subjects were on no RLS
treatment (Table 1).

Primary Variables
Table 2 gives individual subject information for the
markers of interest. There was a significant difference
in the extent of silent cerebral microvascular disease
(P=0.015) (Figure 1 and Table 3) and the level of gliosis (P=0.003) (Figure 2 and Table 3) in patients with
RLS compared with controls. All patients and controls
were negative for amyloid beta-protein and tau protein
(Tables 2 and 3).

Secondary Variables
T cells were also increased in RLS compared with controls (P=0.009) (Figure 3 and Table 3). T cells tended to
colocalize with microvascular disease, and the colocalization was significantly greater in patients with RLS
than controls (P=0.003) (Table 3).
By Mann-Whitney U test there was no significant
difference between patients and controls in CD68
(U=22; Z=0; P=1.0) or CD117 (U=18; Z=−0.21958;
P=0.825) (Table 3). There was no evidence of CD19
B-
cell antibody production in patients or controls
(Tables 2 and 3).

Tertiary Variables
Given the small sample size and the fact that not
all the secondary variables differed significantly between groups, further analysis should be considered
exploratory. There was no significant correlation by
Spearman’s rho between RLS duration (rs=0.72;
P=0.17) or severity (rs=−0.41; P=0.49) and microvascular lesion load (Table 1). Chi-square analysis
did not find a significant imbalance of cardiovascular disease (myocardial infarction, congestive heart
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Table 1. Clinical Characteristics of the Patients With RLS and Controls
Age, y

Sex

RLS Duration, y

RLS Severity
Score

Time From IRLS Score
to Autopsy

RLS Treatment

93

F

2

4

3 mo

None

2

79

M

8

12

39 mo

Hydrocodone

3

80

M

13

15

5 mo

Clonazepam

4

65

M

3

28

24 mo

Ropinirole tramadol

5

88

F

27

9

16 mo

None

Age, y

Sex

…

…

…

88

F

…

…

…

2

78

F

…

…

…

3

87

F

…

…

…

4

91

M

…

…

…

5

84

F

…

…

…

6

96

M

…

…

…

7

99

F

…

…

…

Patient No.
1

Control no.
1

8

93

F

…

…

…

9

96

F

…

…

…

RLS severity score is the IRLS, a previously validated scale in which 10 questions are each rated from 0 (no RLS symptoms) to 4 (maximum RLS symptoms)
and then totaled (range, 0–40). RLS treatment is indicated as treatment at the time of death. There is no statistically significant difference in age (U=11; P=0.14)
or sex (P=0.2657 by 2-tailed Fisher’s exact test) between patients and controls. There was not a statistically significant correlation by Spearman’s rho between
RLS duration (rs=−0.72; P=0.17) or severity (rs=−0.41; P=0.49) and microvascular lesion load. IRLS indicates International Restless Legs Syndrome Severity
Scale; and RLS, restless legs syndrome.

Downloaded from http://ahajournals.org by on September 13, 2021

failure, coronary artery disease, cardiac valve disease, cardiac arrhythmia, cardiomegaly) between
the RLS group (3/5 subjects) and the control group
(8/9 subjects) group. By chi-square there was also
no significant difference in other types of cardiovascular risk factors between the groups such as diabetes mellitus (1/5 versus 1/9), hypertension (2/5 versus
7/9), or hyperlipidemia (2/5 versus 6/9). In addition,
chi-square did not show an imbalance of cancer between the RLS group (3/5 subjects) and the controls
(3/9 subjects).

DISCUSSION
The major finding in this autopsy-based study was
that in subjects without a previous history of stroke
or any other neurologic disease, silent ischemic cerebrovascular disease and gliosis in the motor cortex
were more common in RLS subjects than controls.
These findings support previous magnetic resonance imaging findings of an increase in leukoariotic
cerebrovascular disease in patients with RLS and its
allied condition periodic limb movements in sleep
compared with controls.3,4
Additionally, T-c ell infiltration was more common
in subjects with RLS than in controls. These findings
also support previous findings of a link between
RLS and inflammation.5 The immunologic alteration
in the current study suggests that cellular immunity
may be altered in RLS, given the increased T-c ell
invasion (CD3) we found as opposed to humoral

or antibody immunity (CD19—B cells), the first line
immunologic attack system (CD68—m acrophages),
or allergy/anaphylaxis (CD117—m ast cells). On the
other hand, these data are also compatible with the
normal response of the brain to ischemia. At the lesion border in acutely ischemic areas, there is initially
an invasion of polymorphonuclear leukocytes followed soon after by T lymphocytes, B lymphocytes,
mast cells, and activation of microglia. Over the next
few days there is an invasion of macrophages that
eventually become the predominant inflammatory
cell, but evidence also exists that T cells are the leukocytic lineage that may persist for the longest time
after ischemia.14–19 Leukocytic activity during acute
cerebral ischemia may contribute to the inflammatory process and to neuronal injury but may also
later provide protective and reparative functions to
the damaged area. Increased T-c ell activation in our
patients with RLS may simply be compatible with
the increased microvascular lesion load in these
subjects, and may represent a secondary adaptive
neuroprotective response to prior ischemia. On the
other hand, we cannot exclude the possibility that
the T-c ell presence represents an immune manifestation of RLS. One would assume that the microvascular lesions have been present for some time, long
after one would expect macrophage and mast cell
invasion. Macrophages and mast cells were present
in both our patients with RLS and controls, but no
difference was noted in the degree to which these
cell types were present between the 2 groups. The
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CD3 Score

2.9

2.0

2.26

Microvascular
Injury Score

4

5

Avg

0

0
0.044

0

0.470

0.3

0.6

1.0

0.9

0.9

0.9

0.2

0.3

0.4

CD3 Microvascular
Colocalization Score

1.7

2.1

2.3

1.1

2.1

1.1

CD3 Microvascular
Colocalization Score

0

0

0

0

0

0

0

0

0

0

CD19 Score

0

0

0

0

0

0

CD19 Score

0.188

0.1

0.8

0.1

0.2

0.1

0.1

0.1

0.1

0.1

CD68 Score

0.3

0.1

1.1

0.1

0.1

0.1

CD68 Score

1.788

…

1.9

1.6

1.8

1.9

2.1

2.0

1.5

1.5

CD117 Score

1.7

1.2

2.0

0.9

2.1

2.3

CD117 Score

0.533

0.9

1.6

0

0.4

0.2

1.5

0.2

0

0

GFAP Score

2.3

2.2

2.2

1.8

2.3

3.0

GFAP Score

0

0

0

0

0

0

0

0

0

0

Beta-Peptide
Score

0

0

0

0

0

0

Amyloid Beta-
Peptide Score

0

0

0

0

0

0

0

0

0

0

Tau Protein Score

0

0

0

0

0

0

Tau Protein Score

Ten areas of precentral gyrus of cortex (the motor cortex) were examined in a blinded fashion for each subject and rated 0 to 3+ for each entity of interest. The total of ratings for each of 10 areas per patient were added
to get the sum score. Each number in the table is average, that is, the sum score divided by 10. GFAP indicates glial fibrillary acidic protein; and RLS, restless legs syndrome.

0.688

1.1

Avg

9

0

0.1

1.9

7

8

0

0.2

0

0.2

0.9

1.9

5

0.2

3

4

0

0

0.5

0.2

0.1

6

0

0.1

1

2

Control Subjects

0.3

0.4

3

0.2

3.0

2

0.5

CD3 Score

3.0

Microvascular
Injury Score

1

Patients With RLS

Table 2. Average Scores per Subject for Microvascular Injury, CD3, CD3 Microvascular Colocalization Score, CD19, CD68, CD117, GFAP, Amyloid Beta Peptide, Tau
Protein in Subjects With RLS and Control Subjects
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A

B

C

D

Figure 1. Examples of level of microvascular injury score in controls (A and B) and patients with
restless legs syndrome (RLS) (C and D).
A, Score 0; B, score 1; C, score 2; and D, score 3. There is marked increase in microvascular injury in
patients with RLS characterized by intimal fibrosis of artery (arrow). Hematoxylin and eosin stain, ×200.
Patients with RLS had significantly greater silent microvascular disease than controls (P=0.015). See
details in Tables 2 and 3.
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fact that T cells are more prominent in the subjects
than the controls suggest that the microvascular lesions observed are chronic rather than acute since
T cells persist in the context of vascular insult long
after other cell types have diminished or disappeared.14–19 Other cell types may have diminished
to the point that previous differences between subjects and controls, in the degree to which these cell
types were present, are no longer detectable.

The major limitation to this study was the small
sample size. Autopsy cases of subjects with RLS having little to no other neurologic abnormality clinically or
neuropathologically is very rare. As our methodology
excluded subjects with other neurologic insults, our
sample size was of necessity small. Another limitation
was the possibility that RLS treatment could cause
the microvascular disease, but this is unlikely given
a previous study showing that treatment ameliorates

Table 3. Statistical Comparison Between RLS and Control Group
RLS

Control

M±SD

Mdn (QR)

M±SD

Mdn (QR)

Test Statistic

Hedges’ g

Power, %

Microvascular injury
score

2.3±1.1

2.9 (1)

0.7±0.8

0.2 (1.0)

U=4, P=0.015

1.6±0.6

77.2

CD3 score

0.3±0.2

0.2 (0.3)

0.0±0.1

0.0 (0.0)

U=4, P=0.009

2.0±0.6

90.4

CD3 MC score

1.7±0.6

2.1 (1)

0.6±0.3

0.6 (0.6)

U=0, P=0.003

2.4±0.7

97.8

CD19 score

0

0

0

0

CD68 score

0.3±0.4

0.1 (0)

0.2±0.2

0.1 (0.0)

U=22, P=1

0.3±0.5

8.5

CD117 score

1.7±0.6

2.0 (0.9)

1.8±0.2

1.9 (0.4)

U=18, P=0.825

−0.2±0.5

6.9

GFAP score

2.3±0.4

2.2 (0.1)

0.5±0.6

0.2 (0.9)

U=0, P=0.003

3.1±0.8

99.9

Amyloid beta-peptide
score

0

0

0

0

Tau protein score

0

0

0

0

Patients with RLS had significantly greater silent microvascular disease (P=0.015) and gliosis as demonstrated by GFAP (P=0.003). T cells, as demonstrated
by CD3, were increased in RLS compared with controls (P=0.009) and tended to colocalize with microvascular disease (P=0.003). Other markers did not differ.
The Hedges’ g statistic indicates the effect size for the difference between means. Power=1−β error probability, for 2-tailed α. CD3 MC score indicates T cell
(CD3) microvascular colocalization; GFAP, glial fibrillary acidic protein; M, mean; Mdn, median; QR, quartile range; and RLS, restless legs syndrome.
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A

B

Figure 2. There is a marked increase in gliosis as demonstrated by GFAP (glial fibrillary acidic
protein) in patients with restless legs syndrome (RLS) (A) compared with controls (B) (P=0.003).
The arrow points to perivascular astrocytes (anti-GFAP stain, ×200). See details in Tables 2 and 3.

the likelihood of developing future cardiovascular
disease.20
Considerations for future research into the immunopathogenesis of RLS include flow cytometry to look
for differences in the T-cell subtypes between subjects
with RLS and controls as well as RNA sequencing relevant to T-cell functioning.

CONCLUSIONS
Patients with RLS had statistically significantly more
silent cerebral microvascular disease and gliosis
than controls, compatible with previous magnetic
resonance imaging studies and with studies showing a link between RLS/periodic limb movements in
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A

B

C

D

Figure 3. Examples of level of T-cell (CD3) staining score in controls (A and B) and patients with
restless legs syndrome (RLS) (C and D).
A, Score 0; B, score 1; C, score 2; and D, score 3. There is marked increase in CD3 staining in patients with
RLS (arrow). Anti-CD3 stain, ×200. T cells, as demonstrated by CD3, were increased in RLS compared
with controls (P=0.009) and tended to colocalize with microvascular disease (P=0.003). See details in
Tables 2 and 3.
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sleep and hypertension, clinical stroke, and cardiovascular disease. Upregulated T-c ell levels in patients with RLS could be predisposing factors for
development of microvascular disease or a secondary phenomenon.
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Data S1.

Supplemental Methods

Tissue processing and Immunohistochemistry
Light microscopy
Briefly, brain tissues were fixed in buffered formaldehyde, dehydrated in graded
alcohols, and embedded in paraffin using standard techniques. Serial 5 µm-thick
sections were cut and stained with hematoxylin and eosin reagent.
Immunohistochemical studies
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For CD3 detection, 5 µm-thick paraffin-embedded sections were cut, deparaffinized,
rehydrated. Slides were placed on the Leica Bond Max IHC stainer. All steps besides
dehydration, clearing and coverslipping are performed on the Bond Max. Slides were
deparaffinized. Heat induced antigen retrieval was performed on the Bond Max using
their Epitope Retrieval 2 solution for 20 minutes. Slides were incubated with Ready-ToUse anti-CD3 (Cat# MM150-10, StatLab McKinney, TX) for one hour. The Bond
Polymer Refine system was used for visualization. Slides were the dehydrated, cleared
and coverslipped.
For CD19, CD68, and CD117 detection, 5 µm-thick paraffin-embedded sections were
cut, deparaffinized, rehydrated. Slides were placed on the Leica Bond Max IHC stainer.
All steps besides dehydration, clearing and coverslipping were performed on the Bond

Max. Slides are deparaffinized. Heat induced antigen retrieval was performed on the
Bond Max using their Epitope Retrieval 1 solution for 20 minutes. Slides were incubated
with Ready-To-Use anti-CD19 (PA0843, Leica Biosystems, Newcastle, Tyne, NE, UK),
Ready-To-Use anti-CD68 (MM36-10, StatLab, McKinney, TX), and Ready-To-Use antiCD117 (PA0007, Leica Biosystems, Newcastle, Tyne, NE, UK) for 15minutes. The
Bond Polymer Refine detection system was used for visualization. Slides were the
dehydrated, cleared and coverslipped.

For GFAP detection, 5 µm-thick paraffin-embedded sections were cut, deparaffinized,
rehydrated. Slides were placed on the Leica Bond Max IHC stainer. All steps besides
dehydration, clearing and coverslipping are performed on the Bond Max. Slides were
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deparaffinized. Heat induced antigen retrieval was performed on the Bond Max using
their Epitope Retrieval 2 solution for 5 minutes. Slides were incubated with Ready-ToUse anti-GFAP (PA0026, Leica Biosystems, Newcastle, Tyne, NE, UK) for 15minutes.
The Bond Polymer Refine detection system was used for visualization. Slides were the
dehydrated, cleared and coverslipped.
Normal lymphoid tissue was used as a positive control for CD3, CD19, and CD68.
Normal gastric tissue was used as a positive control for CD117. Brain tissue with
reactive gliosis was used as a positive control for GFAP. Negative controls were done
omitting primary antibody.

